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Abstract: A pH-sensitive stimulus-response system for 
controlled drug release was prepared by modifying 
nano porous silica nanoparticles (NPSNPs) with poly(4-
vinylpyridine) using a bismaleimide as linker. At physi-
ological pH values, the polymer serves as gate keeper 
blocking the pore openings to prevent the release of 
cargo molecules. At acidic pH values as they can occur 
during a bacterial infection, the polymer strains become 
protonated and straighten up due to electrostatic repul-
sion. The pores are opened and the cargo is released. The 
drug chlorhexidine was loaded into the pores because of 
its excellent antibacterial properties and low tendency 
to form resistances. The release was performed in PBS 
and diluted hydrochloric acid, respectively. The results 
showed a considerably higher release in acidic media 
compared to neutral solvents. Reversibility of this pH-
dependent release was established. In vitro tests proved 
good cytocompatibility of the prepared nanoparticles. 
Antibacterial activity tests with Streptococcus mutans and 
Staphylococcus aureus revealed promising perspectives 
of the release system for biofilm prevention. The devel-
oped polymer-modified silica nanoparticles can serve as 
an efficient controlled drug release system for long-term 
delivery in biomedical applications, such as in treatment 
of biofilm-associated infections, and could, for example, 
be used as medical implant coating or as components in 
dental composite materials.
Keywords: chlorhexidine; controlled drug delivery; dental 
application; pH-responsive release; silica nanoparticles; 
stimulus-responsive.
Introduction
Biofilm-associated diseases belong to the most important 
global health problems. A common attribute of bacteria 
organized in biofilms is their persistent nature and their 
increased resilience and resistance to external influences 
like antiseptics, antibiotics and host defenses [1]. In all 
medical disciplines bacterial biofilms can cause implant-
associated infections, leading to loss of tissue and organ 
functions or even to the implant loss. In dentistry, biofilms 
cause caries and periodontitis, which are among the most 
common bacterial infections in humans [2]. For efficient 
prevention or treatment of biofilm infections several 
systems releasing antibacterial and remineralizing agents 
have been reported, e.g. fluoride (F−) [3–6], calcium (Ca2+) 
and phosphate (PO43−) [7–10] or silver (Ag+) ions [11, 12]. 
Chlorhexidine (CHX) is a widely applied drug because of 
its high antimicrobial activity against gram-positive and 
gram-negative bacteria, fungi and viruses [13]. In addi-
tion, the tendency to induce resistances is very low [14]. 
It is used as a preservative and in disinfectant products as 
well as in oral rinses [15]. Furthermore, CHX inhibits the 
formation of bacterial biofilms by binding to the enamel 
and pellicle. Thus, the accumulation of bacterial cells to 
these surfaces, which is the initial step in the formation of 
biofilms, is prevented [16]. CHX shows a high substantiv-
ity, which denotes the prolonged association with certain 
substrates, like the surfaces of teeth or mucosa within the 
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oral cavity [17]. Therefore, CHX exhibits a reservoir effect. 
After a single rinse, CHX is able to reduce the salivary 
quantity of bacteria for several hours [16]. This made CHX 
to the gold standard for the prevention and treatment of 
microbial infections in dentistry [16].
Nanoporous silica materials have been investigated 
intensely, either as nanoparticles [18–21] or as implant 
surface coatings [22–25] since their first application as 
drug delivery platform in 2001 [26]. Nanoporous silica 
features various properties, which make this material 
interesting for a controlled release system. It offers high 
specific surface areas, large pore volumes and tunable 
pore sizes with narrow pore size distributions to allow 
high cargo loading. Nanoporous silica nanoparticles 
(NPSNPs), in particular, are of great interest to drug deliv-
ery, because their size [27–29], shape [30–35] and surface 
modification [36–38] can be adjusted. NPSNPs can easily 
be synthesized via the sol-gel route with surfactants as 
structure-directing agents [39]. These cytotoxic molecules 
are completely removable by calcination at high tempera-
tures. Although, due to their high versatility and diver-
sity, the toxicity assessment of NPSNPs still needs further 
investigation [40–43], NPSNPs are generally considered 
as safe in vitro and in vivo. The US Food and Drug Admin-
istration (FDA) recently has approved modified silica nan-
oparticles for clinical applications [44].
However, an uncontrolled leaching of antimicrobial 
substances from release systems has several disadvan-
tages. While a burst release can be helpful for acute infec-
tions [23] and may be more effective than a prolonged 
delivery [45], there is a need for stimulus-responsive 
release systems, which are dormant for extended times, 
but will deliver cargo upon a certain trigger. Thus, the drug 
remains within the pores and is only extracted when nec-
essary. Various stimuli were investigated, such as pH value 
[46–49], irradiation [50, 51], temperature [52, 53], redox 
potential [54], enzymatic activity [8] as well as specific 
antibodies [55] or glucose [56]. Systems using the irrevers-
ible cleavage of a chemical bond to remove pore-blocking 
gate keepers [57–59] only lead to a singular release that 
continues even after the stimulus has disappeared. A 
stimulus-responsive system working reversible would be 
more favorable for the desired long-term applications.
The approach, presented in this study, is to use the 
decrease of the pH value, as it can occur during an inflam-
mation [60], as a practical internal trigger, thus providing 
an autarkic release system. By the post-synthetic modi-
fication of NPSNPs with poly(4-vinylpyridine) (PVP), a 
pH-sensitive release system can be generated [61]. PVP is 
commercially available with different chain lengths, so 
that cost- and time-consuming laboratory processes are 
Figure 1: Illustration of uncontrolled and pH-responsive drug deliv-
ery systems based on nanoporous silica nanoparticles (NPSNPs).
For controlled release NPSNPs were post-synthetically modified with 
poly(4-vinylpyridine).
not required. At neutral pH values, the polymer strains rest 
folded in a compact state around the NPSNPs (Figure 1). 
The pore openings are blocked and the drug molecules 
loaded into the pores remain there. At acidic pH values, 
the pyridine units of the polymer become protonated. The 
polymer strains straighten up because of repulsive inter-
actions between the cationic pyridinium units and unseal 
the pores. The drug molecules can be released. After the 
successful treatment of a bacterial infection, the pH values 
return to a physiological state leading to the deprotona-
tion of the polymer strains, which again block the pores, 
saving remaining agents.
A possible application of this system is the contact area 
between a dental restoration and the natural tooth, where 
bacteria like Streptococcus mutans would provoke a locally 
decreased pH by acid production during an infection.
Here, we present the development and the char-
acterisation of a new stimulus-responsive drug release 
system on the base of NPSNPs. Furthermore, we tested 
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all components of the material with regard to their 
 biocompatibility and carried out first investigations on 
the antibacterial properties against Streptococcus mutans 
(S. mutans), typically involved in dental caries, and Staph-
ylococcus aureus (S. aureus), a major acidogenic pathogen 
associated with implant infections.
Results
Modified nanoporous silica nanoparticles
The nanoporous silica nanoparticles (NPSNPs) were syn-
thesized according to an adapted literature procedure of 
Neumann and co-workers [29, 39]. They exhibited a spher-
ical morphology and a narrow polydispersity with a mean 
diameter of 40 nm (Figure 2).
Dynamic light scattering (DLS) measurements 
confirmed these results and indicated a favorable low 
agglomeration tendency in ultrapure water (Supporting 
information). In the XRD pattern (Supporting informa-
tion) a single broad reflection occurred at around 1.8° 2Θ, 
indicating a non-ordered pore structure for NPSNPs. 
Nitrogen sorption measurements showed a specific BET 
surface area of 1500 m2 g−1, a pore volume of 1.1 cm3 g−1 and 
a narrow pore width distribution with mean size of 3.6 nm.
For the construction of a controlled drug delivery 
system, the NPSNPs were modified with an amino-bis-
maleimide linker system and the pH-responsive polymer 
poly(4-vinylpyridine) (PVP). The progress of these reac-
tions was easily monitored by infrared (IR) spectroscopy 
(Figure 3).
Figure 2: Scanning electron micrograph of nanoporous silica 
nanoparticles.
Figure 3: Infrared spectra of unmodified, amino-modified, 
bismaleimide-modified (BMPM-modified) and poly(4-vinylpyridine)-
modified (PVP-modified) nanoporous silica nanoparticles.
As expected, all spectra showed characteristic IR 
absorption bands of silica in the region from 1000 to 
1300  cm−1. The broad band in the range of 3750 cm−1 to 
2800  cm−1 corresponds to the O-H stretching vibration 
of water molecules hydrogen-bonded to surface silanol 
groups or between each other. Its intensity strongly 
decreased after the silanization reaction with (3-amino-
propyl)trimethoxysilane (APTMS). In addition, the band 
at 3742 cm−1, corresponding to free silanol groups [62], 
vanished after the reaction with APTMS. This reaction 
introduces primary aminopropyl groups, which gave rise 
to a broad band centered at 3309 cm−1, corresponding 
to the N-H stretching vibration. Further bands between 
2980  cm−1 and 2850 cm−1 are assigned to symmetric and 
asymmetric C-H stretching vibrations of the propyl residue 
[63].
PVP was attached to the amino-modified particles using 
1,1′-(methylenedi-4,1-phenylene)bismaleimide (BMPM). The 
α,β-unsaturated carbonyl compound with two nucleophilic 
groups can react via a Michael addition with amino groups 
(Figure 4).
After the treatment with BMPM the IR spectrum 
exhibited additional bands at 1713 cm−1 (C = O stretching 
vibration), 1516 cm−1 (aromatic C = C stretching vibration) 
and 1392 cm−1 (C-N-C stretching vibration) [64]. The final 
modification with PVP (Figure 4B) resulted in further 
bands at 1607 and 1414 cm−1 corresponding to the pyridine 
groups [65]. After modification with PVP, the specific BET 
surface area dropped to 110 m2 g−1 and the pore volume to 
0.1 cm3 g−1, respectively. These extensive reductions indi-
cate a pore blocking caused by the PVP strains.
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Measurements of zeta potential ξ of unmodified 
NPSNPs (Supporting information) revealed an isoelec-
tric point at pH 4. At higher pH values the zeta potential 
of the particles became more negative due to the depro-
tonation of silanol groups. After modification with PVP 
the isoelectric point was shifted to a pH value of 7–8. At 
lower pH values, the modified particles are positively 
charged due to protonation of the pyridine groups and at 
higher pH values, possibly residual silanol groups become 
deprotonated.
The hydrodynamic diameter of the PVP-modified par-
ticles was determined in water and diluted  hydrochloric 
acid to investigate the pH response of the polymer. At 
neutral conditions the mean size was approximately 
100  nm with a slight increase of the polydispersity 
(Figure  5A) compared to the unmodified particles. 
The polydispersity index increases from PdI = 0.511 to 
PdI = 0.584 indicating in both cases a broad distribution. 
Figure 4: Michael addition reactions between surface-bound amino 
group and the bismaleimide BMPM and the now attached BMPM 
residue and the polymer poly(4-vinylpyridine) (PVP).
Figure 5: Dynamic light scattering measurements of 
 poly(4-vinylpyridine)-modified nanoporous silica nanoparticles at 
(A) neutral (pH 7), and (B) acidic (pH 4) pH values. The polydispersity 
indices calculated by cumulant analysis are (A) PdI = 0.584 and (B) 
PdI = 0.312.
Under acidic conditions, at pH 4, the hydrodynamic diam-
eter enlarged to 250 nm (Figure 5B), which can be ascribed 
to the straightening of the polymer strains due to proto-
nation and the concomitant electrostatic repulsion. Inter-
estingly, the polydispersity (PdI = 0.312) became smaller 
in acidic solution, showing a nearly normal distribution 
of the particle diameter. Probably, the nanoparticles with 
the uncharged polymer corona tended to agglomeration, 
which is absent for the charged particles due to the elec-
trostatic repulsion.
Loading and release of chlorhexidine
With regard to possible dental applications, chlorhex-
idine (CHX) was chosen for drug loading, because this 
antiseptic is currently the gold standard for the treatment 
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of infections in the oral cavity [16]. The loading of unmodi-
fied and PVP-modified NPSNPs was carried out with highly 
concentrated chlorhexidine gluconate stock solutions 
(118 mmol L−1). The gluconate salt has a high solubility in 
water. Chlorhexidine dichloride solutions were tested as 
well, but gave significantly lower amounts of drug loading 
and release (results not shown). For loading PVP-modi-
fied NPSNPs, the pH value of the chlorhexidine gluconate 
solution had to be adjusted to pH 3 with D-gluconic acid in 
order to open the pores. After incubation of the particles 
in the stock solution for 3 days, the loaded amount was 
determined by thermogravimetry. Unmodified NPSNPs 
showed a content of 32 wt% CHX, PVP-modified NPSNPs 
incorporated 24 wt% CHX.
Besides the loading capacity, the release of incorpo-
rated agents is a key factor for the application as drug 
delivery system. The corresponding cumulative release 
curve of CHX from unmodified NPSNPs in PBS at pH 7.4 is 
shown in Figure 6. About 370 microgram of CHX per milli-
gram of NPSNPs are released within 7 days in PBS. A burst 
release during the first 12 h was observed, followed by a 
nearly constant delivery of very small amounts.
After modification of NPSNPs with PVP, the burst 
released amounts of CHX in PBS at pH 7.4 were reduced 
to approximately 220 μg mg−1 (Figure 7). Afterwards, no 
further delivery of CHX was detectable. When adjusting to 
pH 4 with diluted hydrochloric acid, the released amount 
of CHX was considerably increased (Figure 7). This is the 
desired effect of the pH-responsive release. Furthermore, 
the release of PVP-modified nanoparticles loaded from 
a CHX solution was also studied at pH 5. The resulting 
Figure 6: Cumulative release of chlorhexidine from unmodified 
nanoporous silica nanoparticles in phosphate buffered saline at pH 
7.4 and 37 °C.
Figure 7: Cumulative release of chlorhexidine (CHX) from poly(4-
vinylpyridine)-modified nanoporous silica nanoparticles in phos-
phate buffered saline (pH 7.4) and in aqueous hydrochloric acid 
solutions of different pH values.
curve was in between the curves at pH 7.4 and pH 4. Thus, 
the released amount of CHX correlates well with the pH 
value of the medium. We also note that with decreasing 
pH value, the system changes from a clear burst release 
behavior to a more gradual release kinetics. We ascribed 
the very strong burst release of the system at a pH value of 
7.4 to the detachment of drug molecules from the polymer 
corona and the outer surface of the particles and therefore 
introduced additional washing steps in the further release 
studies.
The reversibility of the pH-responsive drug delivery 
system was investigated in detail using consecutive pH 
changes. For this purpose, PVP-modified NPSNPs loaded 
with CHX were dispersed in PBS at pH 7.4 for a certain 
time, separated from the solution by centrifugation and 
then re-dispersed in an aqueous hydrochloric acid solu-
tion at pH 4. This procedure was repeated several times 
and the corresponding release was monitored at every 
pH change (Figure 8). To eliminate the influence of the 
uncontrolled burst release observed at pH 7.4 (Figure 7) 
the PVP-modified NPSNPs were washed carefully before 
usage to remove all CHX which is potentially adsorbed on 
the polymer corona.
At physiological conditions the release rate was low, 
but it increased considerably at acidic pH values. The 
subsequent neutralization by redispersion in PBS leads 
to an almost complete stop of the release. Thus, the 
PVP-modified NPSNPs build up a reversible pH-sensitive 
release system. To release a higher amount of cargo, low 
pH values are necessary, as they can occur, e.g. during a 
bacterial infection.
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Figure 8: Verification of the reversibility of the release of chlorhex-
idine (CHX) from poly(4-vinylpyridine)-modified nanoporous silica 
nanoparticles by consecutive changes of the pH value from 7.4 
(phosphate buffered saline, gray regions) to pH 4 (aqueous hydro-
chloric acid, blue regions).
Values were normalized to the final chlorhexidine concentration 
released in the experiment.
Figure 9: Cytocompatibility of bare (silica) and chlorhexidine-
loaded unmodified nanoporous silica nanoparticles (silica+CHX) for 
gingiva fibroblasts showing the metabolic activity as determined by 
the MTT assay.
Cytocompatibility
The cytocompatibility of the drug delivery systems was 
tested by determining the metabolic activity of gingiva 
fibroblasts in cell cultures where the concentration of 
nanoparticles was increased stepwise. For this purpose, 
the unmodified and PVP-modified NPSNPs, respectively, 
were added to pre-cultured fibroblasts and incubated for 
24 h. The metabolic activity was determined by using the 
well-established MTT assay, which is based on the cel-
lular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide, and the LDH assay, which shows 
the cellular membrane damage by detecting lactate dehy-
drogenase from the inside of the cells.
Whereas the metabolic activity of fibroblasts in pres-
ence of NPSNPs (Figure 9) was similar to the control even 
at high concentrations, a loading with the antiseptic drug 
changed cellular response.
NPSNPs loaded with CHX revealed good cytocompati-
bility up to a concentration of 25 μg mL−1. Above this value, 
the metabolic activity dramatically dropped to 10%. Due 
to these findings, the cytocompatibility was reviewed 
using lower particle concentrations (Figure 10).
The metabolic activity decreased with increasing nan-
oparticle concentration. The results of the LDH assay indi-
cated a membrane damage of approximately 5% to 18%, 
which corresponded with the finding of the MTT assay.
After upgrading the uncontrolled drug delivery system 
to a controlled one by modification with the pH-respon-
sive polymer PVP, the cytocompatibility was reviewed 
again (Figure 11).
Used directly, PVP-modified NPSNPs loaded with CHX 
posed a cytocompatibility which was comparable to that 
of the unmodified NPSNPs (Figure 11A) and bare CHX. To 
separate between the effects of the additional polymer 
coating and the antiseptic drug, the loaded PVP-modified 
NPSNPs were washed with PBS (pH 7.4) for 8 h and 1 week 
to remove potentially adsorbed chlorhexidine. The latter 
procedure was able to improve the cytocompatibility 
drastically up to a very high maximum concentration of 
200 μg mL−1. The results of the LDH assay corresponded 
very well to these findings, with no membrane damage 
detectable in the case of those nanoparticles which were 
washed for 1 week. Without long-term washing, the mem-
branes of gingiva fibroblasts were damaged totally when 
the concentration of the loaded PVP-modified NPSNPs 
exceeded a concentration of 50 μg mL−1.
Antibacterial activity
For the investigation of the antibacterial activity of nano-
particles loaded with CHX, two human pathogens were 
chosen as model organisms. S. mutans is responsible for 
caries and secondary caries at dental fillings, whereas S. 
aureus is a major pathogen associated with implant-asso-
ciated infections [66–68]. Both are aerobic, Gram-positive 
cocci.
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Figure 10: Review of cytocompatibility of nanoporous silica 
nanoparticles loaded with chlorhexidine (silica+CHX) for gingiva 
fibroblasts.
Evaluation of cellular response with regard to (A) metabolic activity, 
determined with the MTT assay; (B) membrane degradation, deter-
mined with the LDH assay.
Figure 11: Cytocompatibility of chlorhexidine (CHX) and 
 poly(4-vinylpyridine)-modified nanoporous silica nanoparticles 
loaded with CHX (silica-PVP+CHX) for gingiva fibroblasts.
Evaluation of cellular response with regard to (A) metabolic activ-
ity, determined with the MTT assay; (B) membrane degradation, 
determined with the LDH assay. In order to avoid action from the 
non-intentional release of CHX adsorbed on the outer surface of 
the polymer-modified nanoparticles, the loaded PVP-modified 
NPSNP were washed additionally for eight hour (8 h) or 1 week (1 w). 
No  membrane degradation was detectable for nanoparticles which 
had been washed for 1 week.
To determine the antibacterial efficacy of CHX-loaded 
NPSNPs, investigations on bacteria suspensions and 
matured biofilms (Figure 12) were carried out. The antibac-
terial activity was determined with the well-established 
resazurin assay. With regard to the previous cytocom-
patibility testing (Figures 9 and 10), concentration in the 
range of 5 μg mL−1 to 50 μg mL−1 were chosen.
The antibacterial efficiencies of CHX released from 
unmodified NPSNPs were negligible for the treatment of 
matured biofilms of S. mutans and S. aureus. Only for a 
concentration of 50 μg mL−1, a slight decrease of the rela-
tive metabolic activity of S. aureus was observed. This 
changed dramatically when the loaded nanoparticles 
were added to bacterial suspensions, i.e. growing bio-
films. Exceeding the concentration of 5 μg mL−1 of the CHX-
loaded nanoparticles leads to total inhibition of bacteria, 
their relative metabolic activity dropping to less than 5%. 
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Figure 12: Antibacterial activity of unmodified nanoporous silica 
nanoparticles loaded with chlorhexidine against (A) Streptococcus 
mutans and (B) Staphylococcus aureus in bacteria suspensions and 
mature biofilms measured with the resazurin assay.
There were no significant differences observable between 
the two both bacterial species.
To assess the inducible antimicrobial activity of 
drug-loaded PVP-modified NPSNPs in response to a pH 
decrease, bacterial suspensions of either S. aureus or 
S. mutans were incubated with such NPSNPs. It can be 
seen from Figure 13 that disinfectant-bearing NPSNPs are 
active against both types of bacteria, inhibiting the bac-
terial growth completely except when used at the lowest 
concentration of 5 μg mL−1. The action of the PVP-modified 
and CHX-loaded nanoparticles after several washing steps 
was reviewed in order to exclude antibacterial effects orig-
inating from uncontrolled CHX release from the polymer 
coating. It can clearly be seen that washing – either once 
or multiple times – does not significantly affect the anti-
bacterial action against S. mutans. For S. aureus the same 
effect was observed, however only for NPSNPs concen-
trations higher than 50 μg mL−1. During the bacterial cell 
culture experiments, we monitored the pH change of 
the medium. In experiments, where only PVP-modified 
NPSNPs without drug cargo were used, bacterial growth of 
S. mutans and S. aureus was observed resulting in a down-
shift of the pH value to 5.5 and 6. In those experiments, 
where the metabolic activity or viability of the bacteria 
was low due to drug action, the pH value did not change 
significantly and remained neutral to slightly alkaline.
It thus becomes obvious that with the experimental 
set-up used here, for successfully combating a bacterial 
infection a sufficient amount of CHX had to be present in 
the culture at a neutral pH value. This could be a hint that 
actually CHX adsorbed in the polymer corona or leaching 
out of the pores is the effective agent.
Discussion
The aim of this study was the development of a controlled 
drug delivery system with antibacterial properties for 
clinical application. For this purpose, the antimicrobial 
agent should be released at acidic pH levels characteristic 
for caries and tissue inflammation sites [60]. The mutans 
streptococci and lactobazilli are able to secret organic 
acids as products of glycoside fermentation [69]. This trig-
gers local acidification processes, which favors the coloni-
zation of further acid-tolerant pathogenic bacteria [69]. As 
releasable disinfectant agent the chlorhexidine gluconate 
(CHX) was chosen, because of its well-known and compre-
hensively investigated antiseptic efficacy against bacteria 
in the oral cavitity [70].
To enable a wide range of applications, we used bio-
compatible nanoporous silica as a base material for the 
design of the release system. It can be employed as a 
surface coating on implants or in the form of nanoparticles 
[41] which can be applied directly or as part of a compos-
ite material like dental fillings [71]. Within our study, we 
were able to synthesize monodisperse, non-agglomerat-
ing NPSNPs with a high BET surface area and a large pore 
volume as shown by the results of SEM, DLS and sorption 
measurements. The further subsequent modifications of 
the particles with the amino-bismaleimide linker system 
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APTMS-BMPM and the pH-responsive polymer poly(4-
vinylpyridin) (PVP) were proven by the corresponding 
bands in the IR spectra and the increase of particle diam-
eter of 100 nm appearing in DLS investigations. An addi-
tional extensive reduction of accessible BET surface area 
to 7.3% of the initial value and the smaller pore volume 
indicated the desired pore blocking caused by the PVP 
corona on the outer surface of the NPSNPs.
For unmodified NPSNPs, zeta potential measure-
ments showed an isoelectric point of 4 and a negative 
charge of the particles arising at higher pH values due to 
the deprotonation of silanol groups. After modification 
with PVP, the isoelectric point was shifted to a pH value 
in the range of 7–8. Thus, at physiological pH values the 
polymer strains appear to remain nearly unprotonated. 
These results are close to those of other studies [72, 73], 
but differ somewhat due to the different constitution of 
the PVP-modified nanoparticles. We observe a higher 
isoelectric point as in those studies which may be caused 
by a more complete coverage of the NPSNPs with PVP. At 
lower pH values the zeta potential of the PVP-modified 
NPSNPs became more positive because of the increasing 
protonation of the pyridine groups. DLS measurements 
under neutral and acidic conditions demonstrated that 
Figure 13: Antibacterial activity of as-manufactured and (single washing was carried out in PBS under ultrasonic treatment for 5 min fol-
lowed by centrifugation, for multiple washing this procedure was carried out three times in total) poly(4-vinylpyridine)-modified NPSNPs 
loaded with CHX (silica-PVP+CHX) against (A) Streptococcus mutans and (C) Staphylococcus aureus and the corresponding pH values of the 
cell cultures of (B) Streptococcus mutans and (D) Staphylococcus aureus. Antibacterial activity was measured with resazurin assay.
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the particle hydrodynamic diameter increased to about 
150% when the particles were placed in an acidic solu-
tion, due to the protonation and the concomitant electro-
static repulsion the polymer strains. This result indicates 
a close packing of the PVP molecules at neutral pH and an 
expansion of the polymer strains under acidic conditions. 
All these results showed the general suitability for a pH-
responsive release.
By simple immersion procedures, we were able to 
incorporate a high amount of the CHX into NPSNPs. 
 Thermogravimetric analysis revealed a high loading of 32 
wt% CHX for unmodified and 24 wt% CHX for PVP-modi-
fied NPSNPs. With the exception of Zhang and co-workers, 
who were able to incorporate even 62.9 wt% of chlorhex-
idine diacetate into nanoporous SBA-15 particles [20], our 
values were much higher or very close to the findings of 
other studies [74, 75]. The slight decrease of the loading 
after modification with PVP is caused by the additional 
mass of the polymer corona. Thermogravimetric analysis 
indicated a polymer content of approximately 20 wt%.
All types of particles loaded with CHX show a very 
high initial burst release, releasing a high amount of 
cargo at the beginning even at physiological pH values. 
The only exception are PVP-modified NPSNPs which were 
washed for 1 week before testing. Due to the high incuba-
tion concentrations of CHX, an extensive amount of agent 
may be absorbed in the polymer coating of particles and 
become released within the first minutes of the experi-
ment. The initially released amount of CHX from unmodi-
fied NPSNPs corresponds to a concentration of 1.6 mg mL−1 
in the release medium; for PVP-modified NPSNPs, the cor-
responding concentration amounts to 1.3 mg mL−1. These 
values are nearly one order of magnitude higher than the 
minimal inhibitory concentrations (MICs) for the tested 
bacterial species (1.6 μg mL−1 for S. aureus and 2.5 μg mL−1 
for S. mutans) [76, 77]. After the burst release, all curves 
showed a nearly constant release with similar slopes. This 
leads to the assumption that the release depended on time 
rather than on the amount of incorporated CHX. In con-
trast to unmodified nanoparticles, the release of CHX from 
PVP-modified NPSNPs was controllable. Low pH values 
of pH 4 or pH 5 lead to a clear enhancement of CHX in 
the medium, whereas at pH 7.4, no significant additional 
release is observed after the initial burst release. The 
reversibility of the release system was tested by switching 
between pH values of 7 and 4 (Figure 8). A fast and well-
defined answer of the system was observed. The amounts 
of CHX delivered in the intervals at pH 4 during later steps 
decreased with every step of pore opening (Figure  8), 
which is due to the fact that in the series of burst releases at 
pH 4, the concentration of CHX stored in the nanoparticles 
decreased. Therefore, with the combination of NPSNPs as 
host material and PVP as a pH-responsive gate keeper, 
a fast and reversible stimulated release system can be 
constructed.
We investigated possible cytotoxic effects caused 
by NPSNPs and chlorhexidine on gingiva fibroblasts to 
ensure the cytocompatibility in the concentration range of 
interest. As shown in Figure 9, only CHX-loaded unmodi-
fied NPSNPs exhibited cytotoxic effects. With regard to the 
well described good cytocompatibility of silica nanoparti-
cles and the cytotoxicity of CHX on gingiva fibroblasts, the 
antiseptic drug is most likely responsible for the adverse 
effects on the cells [78]. Only a maximum concentration of 
25 μg mL−1 for unmodified NPSNPs loaded with CHX could 
guarantee cytocompatibility. A detailed study revealed 
a clear relationship between the concentration and the 
metabolic activity of gingiva fibroblasts (Figure 11). The 
LDH assay indicated that CHX caused a minor damage of 
cell membranes, which corresponded to the result of the 
MTT assay. For PVP-modified NPSNPs loaded with CHX, 
the results of the cytocompatibility testings were very 
similar. The system is cytocompatible up to a concentra-
tion of 25 μg mL−1. However, the cytocompatibility could 
be considerably improved by additional washing steps 
to remove drugs adsorbed on the outer surface or in the 
polymer corona of the nanoparticles. After washing for 
1 week at neutral pH, the nanoparticles are cytocompat-
ible up to very high concentrations of 200 μg mL−1.
Unmodified NPSNPs loaded with CHX were effec-
tive against both bacterial strains tested. This could be 
explained by the high loading capacity and solubility of 
CHX in aqueous media. NPSNPs themselves had no anti-
bacterial effects indicating a good setup for our investi-
gations. In detailed investigations on the antibacterial 
effect with concentrations higher than 5 μg mL−1, a strong 
antibacterial effect against suspensions of S. mutans and 
S.  aureus was observed. In contrast, for mature biofilms 
no antibacterial effect could be detected. Biofilms are 
known to be highly tolerant against antimicrobials [79]. 
However, the reduced antibacterial effect of CHX may 
also be caused by a pH depended efficacy of the antisep-
tic drug. A proposed mode of action of CHX is the inter-
action of the drug molecule, which is positively charged 
under neutral pH conditions, and membrane of bacteria, 
which is negatively charged [6, 15]. Under acidic condi-
tions, these membranes may be partly protonated, which 
reduces the interaction with CHX [76, 80]. In most cases, 
the optimum pH range for CHX applications is given as pH 
5.5 to pH 7, but this varies with the type of organism and 
buffer [76, 77, 80]. It is known that the antibacterial activ-
ity of CHX against S. aureus and Escherichia coli increases 
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with rising pH value, whereas the effect on Pseudomonas 
aeruginosa (P. aeruginosa) is reversed [76]. In contrast, an 
in vitro study did not demonstrate any influence on the 
antibacterial efficiency of chlorhexidine digluconate in 
the range of pH 5.0–pH 9 against S. aureus and P. aerugi-
nosa [6].
The cytocompatibility of PVP-modified NPSNPs is 
maintained up to a concentration of 25 μg mL−1 and could 
be further improved by washing for 1 week. PVP-modified 
NPSNPs loaded with CHX exhibited antibacterial effects 
when applied with concentrations higher than 5 μg mL−1. 
However, for acidogenic S. mutans, no pH downshift was 
observed after incubation with CHX loaded nanoparti-
cles. This indicates an antibacterial activity from the early 
beginning without bacterial growth and acidification 
of culture medium. The reason may be an uncontrolled 
release of adsorbed CHX. For S. aureus, no antibacterial 
effect of pH-responsive NPSNPs could be expected. It is a 
non-acidogenic bacterium so that the pH level does not 
fall below pH 6 during cultivation. This is insufficient 
for the induction of drug release. However, an antibacte-
rial effect for concentrations higher than 5 μg mL−1 was 
observed which strengthens the hypothesis of unspecific 
CHX leaching.
Summarizing, the biological evaluation of the devel-
oped NPSNPs shows that the therapeutic window of 
our drug delivery systems, where fibroblasts stay vital 
whereas bacterial growth is inhibited, depends strongly 
on the number and the constitution of bacteria to combat. 
Unmodified NPSNPs loaded with CHX are applicable in the 
range 10 μg mL−1–20 μg mL−1. Currently, the pH-controlled 
release has to be optimized for the proposed biomedical 
applications. For example, a chemical crosslinking, which 
compresses the polymer corona, or extended washing 
could prevent the unwanted release at physiological pH.
Conclusion
To construct a pH-sensitive stimulus-response release 
system, PVP was attached to amino-modified NPSNPs 
by the use of an APTMS-BMPM-based linker system. CHX 
was successfully loaded into the particles by incubation 
from an acidified solution of its gluconate salt, leading to 
high amounts of adsorbed drug. The functionality of the 
system was proven by the successive exchange of release 
media with altering pH values of 4 and 7.4, showing a fast 
and reversible release behavior. This proves the general 
suitability of the system for a stimulus-responsive and 
repeated release with high reversibility. Furthermore, 
we were able to determine therapeutic windows for CHX 
loaded in unmodified and PVP-modified NPSNPs by 
detailed investigation of the cytocompatibility and the 
antibacterial effect. First antibacterial experiments with 
PVP-modified NPSNPs indicated some leaching effects 
under cell culture conditions, probably liberated from the 
outer surface or the polymer shell. This finding demands 
for further improvements towards a clinical application. 
This study, however, documents a proof-of-principle for 
the generation of pH-stimulus responsive nanoparticles 
loaded with antibacterial agents and could serve as a 
promising basis for the development of biofilm-inhibiting 
biomaterials.
Statement of authors
This study is a proof-of-principle for a self-sufficient 
controlled drug delivery system for the local treatment 
of biofilm-associated infections. We have established a 
reversible, pH-responsive release system for the antisep-
tic agent chlorhexidine. This system can be triggered by 
the acidic milieu present in infections of acid-producing 
bacteria, which play an important part during the forma-
tion of secondary caries and inflammations in the oral 
cavity. Using a novel, cost and time-saving approach, 
NPSNPs were stepwise modified with commercially avail-
able amino silane, bismaleimide and the pH-responsive 
polymer poly(4-vinylpyridine). With the occurrence of an 
acidic pH value, the polymer chains become protonated, 
stretch and repel each other and open the gates to the 
drug reservoir. With detailed associated cytocompatibility 
and antibacterial activity testing in vitro, we were able to 
monitor the development and the efficacy of the system 
which however will still need further development, for 
example with regard to prohibiting unintentional release 
of drug adsorbed on the polymer shell of the particles.
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